Get the app
US › Healthcare

Puma Biotechnology Inc (PBYI)

US · Healthcare · Biotechnology

$9.52+1.38%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$56.5M
Revenue YoY
+7.8%
Net profit
$8.2M
Profit YoY
+39.9%
EPS
$0.16
EPS estimate
$0.06
Net margin
14.5%

EPS came in at 0.16 against a street estimate of 0.06 — a beat of 166.7%.

Key statistics

Market cap
$477.5M
P/E
18.1
Forward P/E
3.5
P/B
3.41
Book value
$2.71
EPS (TTM)
$0.51
52-week high
$9.74
52-week low
$4.37
50-day MA
$8.63
200-day MA
$7.17
Beta
1.23

Analyst view

Analysts rate Puma Biotechnology Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $6.00.

Shareholding

Insiders
15.28%
Institutions
75.66%

Largest institutional holders

FundStake
BlackRock Inc6.97%
American Century Companies Inc4.49%
Acadian Asset Management LLC3.96%
Renaissance Technologies Corp3.76%
Vanguard Capital Management, LLC3.52%
Vanguard Portfolio Management, LLC3.36%
LSV Asset Management3.13%
Dimensional Fund Advisors, Inc.2.94%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Puma Biotechnology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.